

Update: Candida auris Cases in Kindred Hospital, Santa Ana

March 28, 2019

Multiple patients colonized with *Candida auris* (*C. auris*) have been identified recently at Kindred Hospital, Santa Ana. These patients are the first identified in Southern California.

OCHCA has followed up on all patients discharged from Kindred Hospital, Santa Ana since February 1, 2019. For all patients who currently reside at a hospital or skilled nursing facility, OCHCA has contacted that patient's facility and provided recommendations to institute appropriate infection control measures and arrange *C. auris* screening.

Updated Recommendations:

- **All healthcare facilities should perform admission screening for *C. auris* and institute empiric Contact precautions for patients admitted from Kindred Hospital, Santa Ana.** Patients who have been previously screened at Kindred, Santa Ana should still have admission screening performed at the accepting facility.
- **Admission screening for *C. auris* should include a composite swab of the axilla and groin as well as a swab of the nares.** The CDC recommends inclusion of swabbing of the nares to optimize testing yield.
- **Hospitals accepting patients from Kindred Hospital, Santa Ana should contact OCHCA at 714-834-8180 to arrange for receipt of screening swabs and coordinate their transfer to a public health laboratory for testing.** Testing for *C. auris* colonization is available through the Centers for Disease Control and Prevention (CDC) Antibiotic Resistance Laboratory Network. At this time, commercial testing for *C. auris* screening is not available. *C. auris* colonization testing by culture generally takes 7-21 days to result.
- **Facility-to-facility communication is critical when transferring a patient who is suspected or confirmed to be colonized or infected with *C. auris*.** Any accepting facility should be made aware of the patient's status.
- **Hospitals that frequently share patients with Kindred Hospital, Santa Ana are currently recommended to perform species identification of all clinical *Candida* isolates, regardless of specimen source.** OCHCA has contacted the affected facilities regarding this recommendation. Enhanced *Candida* speciation will help assure identification of *C. auris*. No additional surveillance or infection control measures are recommended for these hospitals at this point.

- **Facilities that do not frequently share patients with Kindred Hospital, Santa Ana are not currently recommended to change their laboratory testing or surveillance practices.**

Background:

C. auris is an emerging yeast that is multidrug resistant and has a propensity to spread in healthcare settings. Outbreaks have occurred in several states, primarily in the eastern half of the country. One case was identified in Northern California in 2018. Early detection of *C. auris* and rigorous adherence to infection control measures is essential for containing its spread in healthcare facilities.

Infection Control:

Appropriate infection control precautions for patients suspected or confirmed to be colonized or infected with *C. auris* include:

- Place patient in a single-patient room and use Standard and Contact Precautions.
- Emphasize adherence to hand hygiene.
- Use dedicated medical equipment.
- Minimize the number of healthcare staff caring for the patient.
- Clean and disinfect the patient care environment and reusable equipment (daily and terminal cleaning) with recommended products (see below) throughout the unit or facility where patients with *C. auris* are located.

Patients have remained colonized for several months, even after an active infection has resolved. The maximum amount of time that a patient can be colonized is unknown. There are currently no data on the efficacy of decolonization for patients with *C. auris*, such as the use of chlorhexidine or topical antifungals.

Laboratory Testing:

C. auris has been identified from many body sites including bloodstream, urine, respiratory tract, biliary fluid, wounds, and external ear canal. The CDC recommends that all yeast isolates obtained from a normally sterile site (e.g., bloodstream, cerebrospinal fluid) be identified to the species level so that appropriate initial treatment can be administered based on the typical, species-specific susceptibility patterns. In addition, yeast isolates obtained from non-sterile sites (e.g., urine, respiratory tract) can be identified to the species level as part of enhanced surveillance for *C. auris*.



CD HEALTH ALERT

Critical Communicable Disease Information for Orange County Medical Providers

Cleaning Agents:

CDC recommends the use of an Environmental Protection Agency (EPA)-registered hospital-grade disinfectant effective against *Clostridioides difficile* spores (List K, found at <https://www.epa.gov/pesticide-registration/list-k-epas-registered-antimicrobial-products-effective-against-clostridium>). Quaternary ammonium compounds that are routinely used for disinfection may not be effective against *C. auris*, and data on use of hands-free disinfection methods, like germicidal UV irradiation, are limited.

Treatment:

Consultation with an infectious disease specialist is highly recommended for patients infected with *C. auris*. Echinocandins should be used for initial treatment in most cases. See [CDC's guidance](#) for more detailed treatment information.

For additional information, visit <https://www.cdc.gov/fungal/candida-auris/index.html>

Contact Information:

Healthcare facilities or laboratories that suspect they have a patient with *C. auris* colonization or infection should contact the **Orange County Health Care Agency Epidemiology and Assessment Division** **immediately at 714-834-8180.**

Update: *Candida auris* in Orange County

April 16, 2019

Patients colonized with *Candida auris* (*C. auris*) have been identified recently at multiple healthcare facilities in Orange County. Colonized patients have been identified in Kindred Hospital, Santa Ana. Subsequent point prevalence surveys conducted in skilled nursing facilities who provide ventilator care (vSNFs) and who frequently share patients with Kindred, Santa Ana have identified additional suspect or confirmed positive patients. Some vSNF patients who tested positive have a history of admission to Kindred, Santa Ana, others do not. These patients are the first identified *C. auris* cases in Southern California.

OCHCA is working with all facilities where *C. auris*-colonized patients have been identified to assure that any receiving facilities are informed of the situation when patients are being transferred.

Updated Recommendations:

- **All healthcare facilities should perform admission screening for *C. auris* and institute empiric Standard and Contact Precautions for patients admitted from facilities where *C. auris*-colonized patients have been identified.** Patients who have been previously screened at the facility with *C. auris*-colonized patients should still have admission screening performed at the accepting facility.
- **Admission screening for *C. auris* should include a composite swab of the axilla and groin as well as a swab of the nares.** The CDC recommends inclusion of swabbing of the nares to optimize testing yield.
- **Hospitals accepting patients from facilities where *C. auris*-colonized patients have been identified should contact OCHCA at 714-834-8180 to arrange for receipt of screening swabs and coordinate their transfer to a public health laboratory for testing.** Testing for *C. auris* colonization is available through the Centers for Disease Control and Prevention (CDC) Antibiotic Resistance Laboratory Network. Commercial testing for *C. auris* screening is not available at this time. *C. auris* colonization testing by culture generally takes 7-21 days to result.
- **Facility-to-facility communication is critical when transferring a patient who is suspected or confirmed to be colonized or infected with *C. auris*.** Any accepting facility should be made aware of the patient's status.
- **Hospitals that frequently share patients with Kindred Hospital, Santa Ana are currently recommended to perform species identification of all clinical *Candida* isolates,**

regardless of specimen source. OCHCA has contacted the affected facilities regarding this recommendation. Enhanced *Candida* speciation will help assure identification of *C. auris*. No additional surveillance or infection control measures are recommended for these hospitals at this point.

- **Facilities that do not frequently share patients with Kindred Hospital, Santa Ana are not currently recommended to change their laboratory testing or surveillance practices.**

Background:

C. auris is an emerging yeast that is multidrug resistant and has a propensity to spread in healthcare settings. Outbreaks have occurred in several states, primarily in the eastern half of the country. One case was identified in Northern California in 2018. Early detection of *C. auris* and rigorous adherence to infection control measures is essential for containing its spread in healthcare facilities.

Infection Control:

Appropriate infection control precautions for patients suspected or confirmed to be colonized or infected with *C. auris* include:

- Place patient in a single-patient room and use Standard and Contact Precautions.
- Emphasize adherence to hand hygiene.
- Use dedicated medical equipment.
- Minimize the number of healthcare staff caring for the patient.
- Clean and disinfect the patient care environment and reusable equipment (daily and terminal cleaning) with recommended products (see below) throughout the unit or facility where patients with *C. auris* are located.

Patients have remained colonized for several months, even after an active infection has resolved. The maximum amount of time that a patient can be colonized is unknown. There are currently no data on the efficacy of decolonization for patients with *C. auris*, such as the use of chlorhexidine or topical antifungals.

Laboratory Testing:

C. auris has been identified from many body sites including bloodstream, urine, respiratory tract, biliary fluid, wounds, and external ear canal. The CDC recommends that all yeast isolates obtained from a normally sterile site (e.g., bloodstream, cerebrospinal fluid) be identified to the species level so that appropriate initial treatment can be administered based on the typical, species-specific susceptibility patterns. In addition, yeast isolates obtained from non-sterile sites (e.g., urine, respiratory tract) can be identified to the species level as part of enhanced surveillance for *C. auris*.



CD HEALTH ALERT

Critical Communicable Disease Information for Orange County Medical Providers

Cleaning Agents:

CDC recommends the use of an Environmental Protection Agency (EPA)-registered hospital-grade disinfectant effective against *Clostridioides difficile* spores (List K, found at <https://www.epa.gov/pesticide-registration/list-k-epas-registered-antimicrobial-products-effective-against-clostridium>). Quaternary ammonium compounds that are routinely used for disinfection may not be effective against *C. auris*, and data on use of hands-free disinfection methods, like germicidal UV irradiation, are limited.

Treatment:

Consultation with an infectious disease specialist is highly recommended for patients infected with *C. auris*. Echinocandins should be used for initial treatment in most cases. See [CDC's guidance](#) for more detailed treatment information.

For additional information, visit <https://www.cdc.gov/fungal/candida-auris/index.html>

Contact Information:

Healthcare facilities or laboratories that suspect they have a patient with *C. auris* colonization or infection should contact the **Orange County Health Care Agency Epidemiology and Assessment Division immediately at 714-834-8180.**

Update: *Candida auris* in Orange County

May 30, 2019

Patients colonized or infected with *Candida auris* (*C. auris*) continue to be identified in Orange County.

In communities experiencing *C. auris* outbreaks in this country, colonization rates have consistently been highest in residents of long term acute care hospitals (LTACs) and skilled nursing facilities that provide ventilator care (vSNFs). Accordingly, point prevalence surveys have been completed in all LTACs and vSNFs in Orange County. Over 60 colonized patients have been identified by point prevalence surveys in these facilities. These cases are the first identified in Southern California.

OCHCA is working with all facilities where *C. auris*-colonized patients have been identified to assure that receiving facilities are informed of the situation when patients are transferred. While colonization rates are highest in LTACs and vSNFs, *C. auris* transmission can occur in a variety of healthcare settings. Appropriate infection control measures should be taken by healthcare providers in all settings.

Updated Recommendations:

- **Healthcare facilities should institute empiric Standard and Contact Precautions for:**
 - All patients admitted from all LTACs in Orange County.
 - All patients admitted from vSNFs where *C. auris*-colonized patients have been identified.
- **Admission screening for *C. auris* should be performed by receiving facilities for all patients from the above facilities who may be admitted for a prolonged period (one week or longer).**
 - Admission screening for *C. auris* should include a composite swab of the axilla and groin as well as a swab of the nares. The CDC recommends inclusion of nares swabbing to optimize testing yield.
 - Patients who have been previously screened at a facility with *C. auris*-colonized patients should still have admission screening performed at the accepting facility.
 - Culture testing for *C. auris* colonization is available through the Centers for Disease Control and Prevention (CDC) and takes 7-21 days to result.
 - Hospitals accepting patients from facilities where *C. auris*-colonized patients have been identified should contact OCHCA at 714-834-8180 to arrange for receipt of screening swabs and to coordinate their transfer to a public health laboratory for testing.

- **Facility-to-facility communication is critical when transferring a patient who is suspected or confirmed to be colonized or infected with *C. auris*.** Any receiving facility should be made aware of the patient's status.
- **Hospitals that frequently share patients with Orange County LTACs and/or with vSNFs where *C. auris*-colonized patients have been identified are currently recommended to perform species identification of all clinical *Candida* isolates, regardless of specimen source.** OCHCA has contacted the affected facilities regarding this recommendation. Enhanced *Candida* speciation will help assure identification of *C. auris*. No additional surveillance or infection control measures are recommended for these hospitals at this point.

Background:

Candida auris is an emerging yeast that is multidrug resistant and has a propensity to spread in healthcare settings. Outbreaks have occurred in several states, primarily in the eastern half of the country. One case was identified in Northern California in 2018. Early detection of *C. auris* and rigorous adherence to infection control measures is essential for containing its spread in healthcare facilities.

Infection Control:

Appropriate infection control precautions for patients suspected or confirmed to be colonized or infected with *C. auris* include:

- Place patient in a single-patient room and use Standard and Contact Precautions.
- Emphasize adherence to hand hygiene.
- Use dedicated medical equipment.
- Minimize the number of healthcare staff caring for the patient.
- Clean and disinfect the patient care environment and reusable equipment (daily and terminal cleaning) with recommended products (see Cleaning Agents section below) throughout the unit or facility where patients with *C. auris* are located.

Patients have remained colonized for several months, even after an active infection has resolved. The maximum amount of time that a patient can be colonized is unknown. There are currently no data on the efficacy of decolonization for patients with *C. auris*, such as the use of chlorhexidine or topical antifungals.

Additional infection control recommendations for a variety of healthcare settings can be found at <https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html>.

Laboratory Testing:



CD HEALTH ALERT

Critical Communicable Disease Information for Orange County Medical Providers

C. auris has been identified from many body sites including bloodstream, urine, respiratory tract, biliary fluid, wounds, and external ear canal. The CDC recommends that all yeast isolates obtained from a normally sterile site (e.g., bloodstream, cerebrospinal fluid) be identified to the species level so that appropriate initial treatment can be administered based on the typical, species-specific susceptibility patterns. In addition, yeast isolates obtained from non-sterile sites (e.g., urine, respiratory tract) can be identified to the species level as part of enhanced surveillance for *C. auris*.

Cleaning Agents:

CDC recommends the use of an Environmental Protection Agency (EPA)-registered hospital-grade disinfectant effective against *Clostridioides difficile* spores (List K, found at <https://www.epa.gov/pesticide-registration/list-k-epas-registered-antimicrobial-products-effective-against-clostridium>). Quaternary ammonium compounds that are routinely used for disinfection may not be effective against *C. auris*, and data on use of hands-free disinfection methods, like germicidal UV irradiation, are limited.

Treatment:

Consultation with an infectious disease specialist is highly recommended for patients infected with *C. auris*. Echinocandins should be used for initial treatment in most cases. See [CDC's guidance](#) for more detailed treatment information.

For additional information, visit <https://www.cdc.gov/fungal/candida-auris/index.html>.

Contact Information:

Healthcare facilities or laboratories that suspect they have a patient with *C. auris* colonization or infection should contact the **Orange County Health Care Agency Epidemiology and Assessment Division immediately at 714-834-8180.**

***Candida auris* in Orange County: Update for Skilled Nursing Facilities**

June 10, 2019

Multiple patients colonized or infected with *Candida auris* (*C. auris*) have been identified in Orange County. This cluster of cases is the first identified in Southern California.

C. auris is an emerging yeast that is multidrug resistant, can cause serious invasive infections and has a propensity to spread in healthcare settings. Patients at highest risk are those who have been hospitalized long-term, are ventilated, have a tracheostomy, have an indwelling intravenous catheter, and/or have received multiple rounds of antibiotics. Early detection of *C. auris* and rigorous adherence to infection control measures is essential for containing its spread in healthcare facilities.

Outbreaks have occurred in several states, primarily in the eastern half of the country. In communities experiencing *C. auris* outbreaks, colonization rates have consistently been highest in residents of adult long term acute care hospitals (LTACs) and skilled nursing facilities that provide ventilator care (vSNFs). Colonization has been identified in residents of skilled nursing facilities that do not provide ventilator care, but rates of colonization and illness are much lower in these settings.

Point prevalence surveys, with testing of all residents of a facility, have been completed in all LTACs and vSNFs in Orange County. Multiple LTACs and vSNFs were found to have patients who are *C. auris* colonized; over 60 colonized patients have been identified thus far. Several facilities had no colonized patients identified, and some facilities who initially had colonized patients identified have instituted effective infection control measures and no longer have evidence of ongoing spread of *C. auris*.

OCHCA is working with all facilities with potential ongoing spread of *C. auris* to assure that receiving facilities are informed of the situation when patients are transferred. Transmission can occur in a variety of healthcare settings, and appropriate infection control measures should be taken by in all settings.

Recommendations:

- **Healthcare facilities should institute empiric Standard and Contact Precautions for all patients admitted from LTACs and adult vSNFs with potential ongoing spread of *C. auris*.**
- **Admission screening for *C. auris* should be performed by receiving facilities for all patients from the above facilities who may be admitted for a prolonged period (one week or longer).**
- **Facility-to-facility communication is critical when transferring a patient who is suspected or confirmed to be colonized or infected with *C. auris*.** Any receiving facility should be made aware of the patient's status.

Infection Control:

Appropriate infection control precautions for patients suspected or confirmed to be colonized or infected with *C. auris* include:

- Place patient in a single-patient room whenever possible
- Use Standard and Contact Precautions.
- Emphasize adherence to hand hygiene.
- Use dedicated medical equipment.
- Minimize the number of healthcare staff caring for the patient.
- Clean and disinfect the patient care environment and reusable equipment (daily and terminal cleaning) with recommended products (see Cleaning Agents section on next page) throughout the unit or facility where patients with *C. auris* are located.

SNFs could consider relaxing the requirement for Contact Precautions for certain colonized residents who can perform hand hygiene and have no wounds or indwelling medical devices (e.g., urinary and intravenous catheters and gastrostomy tubes). In these instances, healthcare personnel should still use gowns and gloves when performing tasks that put them at higher risk of contaminating their hands or clothing. These tasks include changing wound dressings and linens and assisting with bathing, toileting, and dressing in the morning and evening.

Patients remain colonized for several months to years, even after an active infection has resolved. There is no treatment for colonization.

Additional infection control recommendations for a variety of healthcare settings can be found at <https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html>.

Admission Screening:

- Admission screening for *C. auris* should include a composite swab of the axilla and groin as well as a swab of the nares. The Centers for Disease Control and Prevention (CDC) recommends inclusion of nares swabbing to optimize testing yield.
- Screening culture testing results are available in 7-21 days.
- Patients who have been previously screened at a facility with potential *C. auris* spread should still have admission screening performed at the accepting facility.
- SNFs accepting patients from facilities where *C. auris*-colonized patients have been identified should contact OCHCA at 714-834-8180 to arrange for receipt of screening swabs and to coordinate their transfer to a public health laboratory for testing.

Patient Activities:

- Patients residing in SNFs who are suspected or confirmed to be colonized with *C. auris* may leave their rooms as long as secretions and bodily fluids can be contained and they can perform hand hygiene prior to leaving the room.
- Patients with *C. auris* can receive physical therapy or other shared services (e.g., physical therapy equipment, recreational resources). Staff providing these services to such a patient should:
 - Not work with other patients while working with the affected patient.
 - Use a gown and gloves when they anticipate touching the patient or potentially contaminated equipment.
 - Whenever possible, see the colonized patient last on a given day.
 - Thoroughly clean and disinfect shared equipment after use.

Laboratory Testing:

C. auris has been identified from many body sites including bloodstream, urine, respiratory tract, biliary fluid, wounds, and external ear canal. The CDC recommends that all yeast isolates obtained from a normally sterile site (e.g., bloodstream, cerebrospinal fluid) be identified to the species level so that appropriate initial treatment can be administered based on the typical, species-specific susceptibility patterns. In addition, yeast isolates obtained from non-sterile sites (e.g., urine, respiratory tract) can be identified to the species level as part of enhanced surveillance for *C. auris*.

Cleaning Agents:

For environmental cleaning of *C. auris*, CDC recommends the use of an Environmental Protection Agency (EPA)-registered hospital-grade disinfectant effective against *Clostridioides difficile* spores (List K, found at <https://www.epa.gov/pesticide-registration/list-k-epas-registered-antimicrobial-products-effective-against-clostridium>). Quaternary ammonium compounds that are routinely used for disinfection may not be effective against *C. auris*, and data on use of hands-free disinfection methods, like germicidal UV irradiation, are limited.

Treatment:

Consultation with an infectious disease specialist is highly recommended for patients infected with *C. auris*. Echinocandins should be used for initial treatment in most cases. Isolates tested in Orange County residents thus far have been susceptible to echinocandins. See [CDC's guidance](#) for more detailed treatment information.

For additional information, visit <https://www.cdc.gov/fungal/candida-auris/index.html>.



CD HEALTH ALERT

Critical Communicable Disease Information for Orange County Medical Providers

Contact Information:

Healthcare facilities or laboratories that have questions or have a suspected case of *C. auris* colonization or infection should contact the **Orange County Health Care Agency Epidemiology and Assessment Division immediately at 714-834-8180.**

Update: *Candida auris* in Orange County

July 2, 2019

Patients colonized or infected with *Candida auris* (*C. auris*) continue to be identified in Orange County.

Point prevalence surveys, with testing of all residents of a facility, have been completed in all long term acute care hospitals (LTACs) and skilled nursing facilities that provide ventilator (vSNFs) in Orange County. Multiple LTACs and vSNFs were found to have patients who are *C. auris* colonized. Over 100 colonized patients have been identified thus far. Several facilities had no colonized patients identified, and some facilities who initially had colonized patients identified no longer have evidence of ongoing *C. auris* spread.

In communities experiencing *C. auris* outbreaks, colonization and disease rates have consistently been highest in residents of LTACs and vSNFs. However, *C. auris* transmission has likely occurred in a variety of healthcare settings during this event. Appropriate infection control measures should be taken by healthcare providers in all settings.

OCHCA is working with all facilities where *C. auris*-colonized patients have been identified to assure that receiving facilities are informed of the situation when patients are transferred.

Updated recommendations for healthcare facilities receiving patients from LTACs and vSNFs with potential ongoing spread of *C. auris*:

- **Hospitals should institute empiric Standard and Contact Precautions.**
- **Skilled nursing facilities should institute either empiric Contact Precautions or Enhanced Standard Precautions, depending on the clinical status of the patient and the *C. auris* epidemiology of the facility.**
- **Admission screening for *C. auris* should be performed by receiving facilities for all patients who may be admitted for a prolonged period (one week or longer) from facilities with potential ongoing *C. auris* spread.**
 - Admission screening for *C. auris* should include a composite swab of the axilla and groin.
 - Screening of nares for colonization has been found to add little sensitivity to axilla and groin swabbing and is no longer recommended.
 - Patients who have been previously screened at a facility with *C. auris*-colonized patients should still have admission screening performed at the accepting facility.
 - Culture testing for *C. auris* colonization is available through the Centers for Disease Control and Prevention (CDC) and takes 7-21 days to result.
 - Receiving facilities should contact OCHCA at 714-834-8180 to arrange for receipt of screening swabs and to coordinate their transfer to a public health laboratory for testing.

- **Facility-to-facility communication is critical when transferring a patient who is suspected or confirmed to be colonized or infected with *C. auris*.** Any receiving facility should be made aware of the patient's status.
- **Hospitals that frequently share patients with Orange County LTACs and/or with vSNFs where *C. auris*-colonized patients have been identified are currently recommended to perform species identification of all clinical *Candida* isolates, regardless of specimen source.** OCHCA has contacted the affected facilities regarding this recommendation. Enhanced *Candida* speciation will help assure identification of *C. auris*. No additional surveillance or infection control measures are recommended for these hospitals at this point.

Background:

Candida auris is an emerging yeast that is multidrug resistant and has a propensity to spread in healthcare settings. *C. auris* is an emerging yeast that is multidrug resistant, can cause serious invasive infections and has a propensity to spread in healthcare settings. Patients at highest risk are those who have been hospitalized long-term, are ventilated, have a tracheostomy, have an indwelling intravenous catheter, and/or have received multiple rounds of antibiotics. Early detection of *C. auris* and rigorous adherence to infection control measures is essential for containing its spread in healthcare facilities.

Outbreaks have occurred in several states, primarily in the eastern half of the country. This cluster of cases is the first seen in Southern California. Early detection of *C. auris* and rigorous adherence to infection control measures is essential for containing its spread in healthcare facilities.

Infection Control:

Appropriate infection control precautions for patients admitted to acute care hospitals who are suspected or confirmed to be colonized or infected with *C. auris* include:

- Place patient in a single-patient room and use Standard and Contact Precautions.
- Emphasize adherence to hand hygiene.
- Use dedicated medical equipment.
- Minimize the number of healthcare staff caring for the patient.
- Clean and disinfect the patient care environment and reusable equipment (daily and terminal cleaning) with recommended products (see Cleaning Agents section below) throughout the unit or facility where patients with *C. auris* are located.

Patients will generally remain colonized for several months, even after an active infection has resolved. The maximum amount of time that a patient can be colonized is unknown. There are currently no data on the efficacy of decolonization for patients with *C. auris*, such as the use of chlorhexidine or topical antifungals.

CD HEALTH ALERT

Critical Communicable Disease Information for Orange County Medical Providers

Suspected or confirmed colonized patients that are admitted to skilled nursing facilities can be cared for using Enhanced Standard Precautions in most instances. See: <https://www.cdph.ca.gov/Programs/CHCQ/LCP/CDPH%20Document%20Library/Enhanced-Standard-Precautions.pdf> for further details on enhanced standard precaution principles.

Additional infection control recommendations for a variety of healthcare settings can be found at <https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html>.

Laboratory Testing:

C. auris has been identified from many body sites including bloodstream, urine, respiratory tract, biliary fluid, wounds, and external ear canal. The CDC recommends that all yeast isolates obtained from a normally sterile site (e.g., bloodstream, cerebrospinal fluid) be identified to the species level so that appropriate initial treatment can be administered based on the typical, species-specific susceptibility patterns. In addition, yeast isolates obtained from non-sterile sites (e.g., urine, respiratory tract) can be identified to the species level as part of enhanced surveillance for *C. auris*.

Cleaning Agents:

CDC recommends the use of an Environmental Protection Agency (EPA)-registered hospital-grade disinfectant effective against *Clostridioides difficile* spores (List K, found at <https://www.epa.gov/pesticide-registration/list-k-epas-registered-antimicrobial-products-effective-against-clostridium>). Quaternary ammonium compounds that are routinely used for disinfection may not be effective against *C. auris*, and data on use of hands-free disinfection methods, like germicidal UV irradiation, are limited.

Treatment:

Consultation with an infectious disease specialist is highly recommended for patients infected with *C. auris*. Echinocandins should be used for initial treatment in most cases. *C. auris* isolates from Orange County cases have thus far been susceptible to caspofungin and amphotericin B. However, strains demonstrating increasing antifungal resistance over time have been seen in outbreaks in other communities. See [CDC's guidance](#) for more detailed treatment information.

For additional information, visit <https://www.cdc.gov/fungal/candida-auris/index.html>.



CD HEALTH ALERT

Critical Communicable Disease Information for Orange County Medical Providers

Contact Information:

Healthcare facilities or laboratories that suspect they have a patient with *C. auris* colonization or infection should contact the **Orange County Health Care Agency Epidemiology and Assessment Division immediately at 714-834-8180.**